Functionalization of Human Serum Albumin by Tyrosine Click
Open Access
- 12 August 2021
- journal article
- research article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 22 (16) , 8676
Abstract
Human serum albumin (HSA) is a promising drug delivery carrier. Although covalent modification of Cys34 is a well-established method, it is desirable to develop a novel covalent modification method that targets residues other than cysteine to introduce multiple functions into a single HSA molecule. We developed a tyrosine-selective modification of HSA. Three tyrosine selective modification methods, hemin-catalyzed, horseradish peroxidase (HRP)-catalyzed, and laccase-catalyzed reactions were performed, and the modification efficiencies and modification sites of the modified HSAs obtained by these methods were evaluated and compared. We found that the laccase-catalyzed method could efficiently modify the tyrosine residue of HSA under mild reaction conditions without inducing oxidative side reactions. An average of 2.2 molecules of functional groups could be introduced to a single molecule of HSA by the laccase method. Binding site analysis using mass spectrometry suggested Y84, Y138, and Y401 as the main modification sites. Furthermore, we evaluated binding to ibuprofen and found that, unlike the conventional lysine residue modification, the inhibition of drug binding was minimal. These results suggest that tyrosine-residue selective chemical modification is a promising method for covalent drug attachment to HSA.Keywords
Funding Information
- Japan Science and Technology Agency (JPMJFR2005)
- Ministry of Education, Culture, Sports, Science and Technology (19H02848)
This publication has 32 references indexed in Scilit:
- Ligand‐Directed Selective Protein Modification Based on Local Single‐Electron‐Transfer CatalysisAngewandte Chemie International Edition, 2013
- Human serum albumin: From bench to bedsideMolecular Aspects of Medicine, 2012
- Impact of albumin on drug delivery — New applications on the horizonJournal of Controlled Release, 2012
- Andromeda: A Peptide Search Engine Integrated into the MaxQuant EnvironmentJournal of Proteome Research, 2011
- Significantly Longer Progression-Free Survival With nab-Paclitaxel Compared With Docetaxel As First-Line Therapy for Metastatic Breast CancerJournal of Clinical Oncology, 2009
- Protein nanoparticles as drug carriers in clinical medicineAdvanced Drug Delivery Reviews, 2008
- Role of Tyr84 in controlling the reactivity of Cys34 of human albuminThe FEBS Journal, 2004
- Binding of Carprofen to Human and Bovine Serum Albumins.Chemical and Pharmaceutical Bulletin, 1994
- Design of compounds having enhanced tumour uptake, using serum albumin as a carrier—part II. In vivo studiesInternational Journal of Radiation Applications and Instrumentation. Part B. Nuclear Medicine and Biology, 1992
- Design of compounds having an enhanced tumour uptake, using serum albumin as a carrier. Part INuclear Medicine and Biology, 1990